271 related articles for article (PubMed ID: 31237800)
1. Rituximab treatment for multiple sclerosis.
Ineichen BV; Moridi T; Granberg T; Piehl F
Mult Scler; 2020 Feb; 26(2):137-152. PubMed ID: 31237800
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for the treatment of multiple sclerosis: a review.
Chisari CG; Sgarlata E; Arena S; Toscano S; Luca M; Patti F
J Neurol; 2022 Jan; 269(1):159-183. PubMed ID: 33416999
[TBL] [Abstract][Full Text] [Related]
3. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X
Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Dunn N; Juto A; Ryner M; Manouchehrinia A; Piccoli L; Fink K; Piehl F; Fogdell-Hahn A
Mult Scler; 2018 Aug; 24(9):1224-1233. PubMed ID: 28762877
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
6. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
D'Amico E; Zanghì A; Chisari CG; Fermo SL; Toscano S; Arena S; Patti F; Zappia M
Mult Scler Relat Disord; 2019 Jan; 27():324-326. PubMed ID: 30471585
[TBL] [Abstract][Full Text] [Related]
8. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
Baber U; Bouley A; Egnor E; Sloane JA
J Neurol; 2018 Oct; 265(10):2342-2345. PubMed ID: 30109480
[TBL] [Abstract][Full Text] [Related]
9. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.
Zhong M; van der Walt A; Campagna MP; Stankovich J; Butzkueven H; Jokubaitis V
Neurotherapeutics; 2020 Oct; 17(4):1768-1784. PubMed ID: 33058021
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C; Bovis F; Novi G; Capobianco M; Lanzillo R; Frau J; Repice AM; Hakiki B; Realmuto S; Bonavita S; Curti E; Brambilla L; Mataluni G; Cavalla P; Di Sapio A; Signoriello E; Barone S; Maniscalco GT; Maietta I; Maraffi I; Boffa G; Malucchi S; Nozzolillo A; Coghe G; Mechi C; Salemi G; Gallo A; Sacco R; Cellerino M; Malentacchi M; De Angelis M; Lorefice L; Magnani E; Prestipino E; Sperli F; Brescia Morra V; Fenu G; Barilaro A; Abbadessa G; Signori A; Granella F; Amato MP; Uccelli A; Gobbi C; Sormani MP
Mult Scler; 2020 Oct; 26(12):1519-1531. PubMed ID: 31573386
[TBL] [Abstract][Full Text] [Related]
12. Therapies for multiple sclerosis targeting B cells.
Milo R
Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for relapsing-remitting multiple sclerosis.
He D; Zhou H; Han W; Zhang S
Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
Brancati S; Gozzo L; Longo L; Vitale DC; Drago F
Front Immunol; 2021; 12():661882. PubMed ID: 34295328
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
16. Rescue Therapy Using Rituximab for Multiple Sclerosis.
Berenguer-Ruiz L; Sempere AP; Gimenez-Martinez J; Gabaldon-Torres L; Tahoces L; Sanchez-Perez R; Diaz-Marin C
Clin Neuropharmacol; 2016; 39(4):178-81. PubMed ID: 27046661
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in paediatric onset multiple sclerosis: a case series.
Salzer J; Lycke J; Wickström R; Naver H; Piehl F; Svenningsson A
J Neurol; 2016 Feb; 263(2):322-326. PubMed ID: 26603152
[TBL] [Abstract][Full Text] [Related]
18. A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus.
Leonidou E; Pantzaris M; Kleopa KA; Loizidou MA; Kyriakides T; Christou YP
Postgrad Med; 2019 Sep; 131(7):486-489. PubMed ID: 31353999
[No Abstract] [Full Text] [Related]
19. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
